Solriamfetol - Revision history

MDElliottMD: Tier 1 taxonomy consolidation: Category:Wake-Promoting Agents to Category:Eugeroics; Category:Norepinephrine Reuptake Inhibitors to Category:Norepinephrine Reuptake Inhibitors (NRIs)

2026-05-21T17:01:59Z

Tier 1 taxonomy consolidation: Category:Wake-Promoting Agents to Category:Eugeroics; Category:Norepinephrine Reuptake Inhibitors to Category:Norepinephrine Reuptake Inhibitors (NRIs)

← Older revision		Revision as of 17:01, 21 May 2026
Line 21:		Line 21:

	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:~~Wake-Promoting Agents~~]]		[[Category:Eugeroics]]
	[[Category:Dopamine Reuptake Inhibitors]]		[[Category:Dopamine Reuptake Inhibitors]]
	[[Category:Norepinephrine Reuptake Inhibitors]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:11Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 2:		Line 2:
	\| brand = Sunosi		\| brand = Sunosi
	\| classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent		\| classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent
	\| mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines — pure reuptake inhibition.		\| mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition.
	\| uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)		\| uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)
	\| starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.		\| starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.
Line 14:		Line 14:
	\| pregnancy = Limited data; pregnancy exposure registry available		\| pregnancy = Limited data; pregnancy exposure registry available
	\| legal = Rx, Schedule IV (US)		\| legal = Rx, Schedule IV (US)
	\| intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles — it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP).		\| intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles, it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP).
	\| pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine).		\| pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine).
	\| effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease.		\| effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease.

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:51:05Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:51, 17 May 2026
Line 20:		Line 20:
	}}		}}

	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Wake-Promoting Agents]]		[[Category:Wake-Promoting Agents]]
	[[Category:Dopamine Reuptake Inhibitors]]		[[Category:Dopamine Reuptake Inhibitors]]
	[[Category:Norepinephrine Reuptake Inhibitors]]		[[Category:Norepinephrine Reuptake Inhibitors]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:19Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 20:		Line 20:
	}}		}}

	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Wake-Promoting Agents]]		[[Category:Wake-Promoting Agents]]
	[[Category:Dopamine Reuptake Inhibitors]]		[[Category:Dopamine Reuptake Inhibitors]]
	[[Category:Norepinephrine Reuptake Inhibitors]]		[[Category:Norepinephrine Reuptake Inhibitors]]

Maintenance script: Create Solriamfetol page (Stahl-sourced detail with skepticism)

2026-05-16T01:56:01Z

Create Solriamfetol page (Stahl-sourced detail with skepticism)

New page

{{MedTemplate
| brand = Sunosi
| classes = Norepinephrine-dopamine reuptake inhibitor (NDRI), wake-promoting agent
| mechanism = Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines — pure reuptake inhibition.
| uses = Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA)
| starting_dose = Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.
| preparations = 75 mg, 150 mg tablets
| fda_max = 150 mg/d
| routes = Oral
| onset = ~30-60 min
| duration = ~9 hours
| halflife = ~7.1 hours
| bioavailability = ~95%
| pregnancy = Limited data; pregnancy exposure registry available
| legal = Rx, Schedule IV (US)
| intro = '''Solriamfetol''' (brand name Sunosi) is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) approved by the FDA in March 2019 for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea. Unlike traditional stimulants (amphetamine, methylphenidate), solriamfetol does not significantly release monoamines from vesicles — it is purely a reuptake inhibitor, which may produce a smoother subjective effect with lower abuse potential. Lower scheduled (CIV) than the traditional stimulants (CII). Not indicated to treat underlying OSA (use with primary OSA therapy such as CPAP).
| pharmacodynamics= Selective inhibitor of DAT and NET. Modest serotonin reuptake inhibition. Does not bind VMAT2 or cause significant monoamine release (contrast with amphetamine).
| effects = Headache, nausea, decreased appetite, anxiety, insomnia, palpitations, blood pressure / heart rate elevation. Avoid in patients with significant cardiovascular disease.
| interactions = <pharmaInteractions/>
}}

[[Category:Stimulants & Wake-Promoting Agents]]
[[Category:Wake-Promoting Agents]]
[[Category:Dopamine Reuptake Inhibitors]]
[[Category:Norepinephrine Reuptake Inhibitors]]